Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA? (omadacycline)

Stock Information for Paratek Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, KLR, PRTK
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, NEWR, PRTK
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CEQP, CELL, DINO, PRTK

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.